Celularity

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to synergize with antibody therapeutics

Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer

FLORHAM PARK, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021.

Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting

FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced financial results for the third quarter ended September 30, 2021, and provided a corporate update.

Celularity Reports Third Quarter 2021 Financial Results and Corporate Update

Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25 years' experience developing life-changing cellular medicines Renowned clinician, scientist and proven executive leader in biotechnology and healthcare with more than 25 years' experience developing life-changing cellular medicines

Celularity Appoints Andrew L. Pecora, M.D.

Celularity is developing off-the-shelf placenta-derived allogeneic cellular therapies that overcome the problem of donor-patient match. The company was spun out from Celgene in 2016-2017.

Celularity: Celgene Spin-Off Developing Allogeneic Therapies

FLORHAM PARK, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today reported financial results for the quarter ended June 30, 2021, and provided a summary of recent corporate highlights.

Celularity Reports Second Quarter 2021 Financial Results

Imugene Limited has provided additional information on a recent partnership with NASDAQ-listed biotech Celurlarity Inc. The clinical-stage immune-oncology company told the local share market it had partnered with Celurlarity to develop an immunotherapy for solid tumours on Thursday, August 5.

Imugene details the fine print on Celularity partnership

Imugene Ltd has entered into a research collaboration with Celurlarity Inc to develop a novel oncolytic virus allogeneic CAR T-Cell immunotherapy combination for the treatment of solid tumors. As part of the partnership, Imugene and Celularity will initially collaborate to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor (CAR) T cellular therapy, CyCART-19, for the treatment.

Imugene enters into strategic partnership with Celularity to develop immunotherapy for solid tumors

SYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company and Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced they have entered into a research collaboration in 2021. As part of the partnership, Imugene and Celularity will initially collaborate to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor (CAR) T cellular therapy, CyCART-19, for the treatment of solid tumors. CyCART-19 is a placental-derived T-cell investigational therapy engineered with a CAR that is cryopreserved and will be available off-the-shelf.

Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors

Celularity announced it closed a merger with GX Acquisition Corp (NASDAQ: GXGX) and provided a corporate update. These are the details.

Celularity Closes Merger With GX Acquisition (GXGX)

Celularity Inc has closed the merger with GX Acquisition Corp (NASDAQ: GXGX), giving Celularity $138 million to push the NK cell and T cell therapies into early-stage trials. The combined company will operate under the name Celularity Inc (NASDAQ: CELU), and its common stock will commence trading on the NASDAQ from Monday (19 July) under the ticker symbol CELU.

Celularity Closes SPAC Merger With GX Acquisition, Trading Starts Monday

GX Acquisition Corp

Common stock of the merged company, Celularity, Inc., to commence trading on the Nasdaq Capital Market under the ticker symbol “CELU” on July 19, 2021

Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update

News for Celularity Stock (CELU)